ZA974223B - Biphenylsulfonamide matrix metalloproteinase inhibitors. - Google Patents

Biphenylsulfonamide matrix metalloproteinase inhibitors.

Info

Publication number
ZA974223B
ZA974223B ZA9704223A ZA974223A ZA974223B ZA 974223 B ZA974223 B ZA 974223B ZA 9704223 A ZA9704223 A ZA 9704223A ZA 974223 A ZA974223 A ZA 974223A ZA 974223 B ZA974223 B ZA 974223B
Authority
ZA
South Africa
Prior art keywords
matrix metalloproteinase
metalloproteinase inhibitors
alkyl
biphenylsulfonamide
biphenylsulfonamide matrix
Prior art date
Application number
ZA9704223A
Other languages
English (en)
Inventor
Patrick Michael O'brien
Drago Robert Sliskovic
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA974223B publication Critical patent/ZA974223B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
ZA9704223A 1996-05-17 1997-05-15 Biphenylsulfonamide matrix metalloproteinase inhibitors. ZA974223B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1746096P 1996-05-17 1996-05-17

Publications (1)

Publication Number Publication Date
ZA974223B true ZA974223B (en) 1997-12-10

Family

ID=21782716

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9704223A ZA974223B (en) 1996-05-17 1997-05-15 Biphenylsulfonamide matrix metalloproteinase inhibitors.

Country Status (22)

Country Link
EP (1) EP0901466B1 (cg-RX-API-DMAC7.html)
JP (1) JP2000511175A (cg-RX-API-DMAC7.html)
KR (1) KR20000011095A (cg-RX-API-DMAC7.html)
CN (1) CN1077885C (cg-RX-API-DMAC7.html)
AT (1) ATE207891T1 (cg-RX-API-DMAC7.html)
BG (1) BG63940B1 (cg-RX-API-DMAC7.html)
BR (1) BR9710841A (cg-RX-API-DMAC7.html)
CA (1) CA2253342A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ294063B6 (cg-RX-API-DMAC7.html)
DE (1) DE69707865T2 (cg-RX-API-DMAC7.html)
DK (1) DK0901466T3 (cg-RX-API-DMAC7.html)
EA (1) EA001561B1 (cg-RX-API-DMAC7.html)
EE (1) EE03965B1 (cg-RX-API-DMAC7.html)
ES (1) ES2167733T3 (cg-RX-API-DMAC7.html)
IL (1) IL126832A0 (cg-RX-API-DMAC7.html)
NO (1) NO312510B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ332711A (cg-RX-API-DMAC7.html)
PL (1) PL186416B1 (cg-RX-API-DMAC7.html)
PT (1) PT901466E (cg-RX-API-DMAC7.html)
SK (1) SK282863B6 (cg-RX-API-DMAC7.html)
WO (1) WO1997044315A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA974223B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69511089T2 (de) * 1994-06-22 1999-12-16 British Biotech Pharmaceuticals Ltd., Cowley Metalloproteinase-inhibitoren
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1998025597A2 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
EP1366765A1 (en) * 1996-12-17 2003-12-03 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
BR9714142A (pt) 1996-12-17 2000-02-29 Warner Lambert Co Uso de inibidores de metaloproteìnases matriciais para tratamento de distúrbios neurológicos e promoção de cicatrização de feridas
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
ID29293A (id) 1997-07-22 1999-01-28 Shionogi & Co KOMPOSISI UNTUK MENGOBATI ATAU MENCEGAH GLOMERULOPATI (Pecahan dari No. W20000054)
DK1047450T3 (da) * 1997-12-23 2003-01-27 Warner Lambert Co Kombinationer af ACE-inhibitorer og MMP-inhibitorer
EP1053226A1 (en) 1998-02-04 2000-11-22 Novartis AG Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
EP1063991A1 (en) * 1998-03-17 2001-01-03 Warner-Lambert Company Llc Statin-matrix metalloproteinase inhibitor combinations
EP0967201A1 (en) * 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
JP4567886B2 (ja) * 1998-07-16 2010-10-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 医薬として使用されるホスフィン酸およびホスホン酸誘導体
HRP20010055A2 (en) * 1998-07-21 2002-04-30 Warner Lambert Co Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
DE19851184A1 (de) * 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1172361A4 (en) * 1999-04-19 2002-05-08 Shionogi & Co SULFONAMIDE DERIVATIVES HAVING OXADIAZOLE CORES
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
SI1249233T1 (sl) 1999-11-26 2009-02-28 Shionogi & Co Antagonisti NPYY5
JPWO2002028844A1 (ja) * 2000-09-29 2004-02-12 塩野義製薬株式会社 チアゾールおよびオキサゾール誘導体
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
MXPA01013326A (es) * 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
WO2003035610A1 (en) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Sulfonamide derivative having mmp inhibitory activity
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
EP1689716A1 (en) * 2003-12-04 2006-08-16 Wyeth Biaryl sulfonamides and methods for using same
JP2007530546A (ja) 2004-03-22 2007-11-01 サザン リサーチ インスティチュート マトリックスメタロプロテイナーゼの非ペプチドインヒビター
CN101279956B (zh) * 2008-04-25 2011-06-15 南昌大学 一种基质金属蛋白酶抑制剂及合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
DE69511089T2 (de) * 1994-06-22 1999-12-16 British Biotech Pharmaceuticals Ltd., Cowley Metalloproteinase-inhibitoren

Also Published As

Publication number Publication date
IL126832A0 (en) 1999-08-17
ES2167733T3 (es) 2002-05-16
BG102918A (en) 1999-09-30
ATE207891T1 (de) 2001-11-15
PT901466E (pt) 2002-04-29
NO312510B1 (no) 2002-05-21
DE69707865T2 (de) 2002-05-02
SK282863B6 (sk) 2002-12-03
PL186416B1 (pl) 2004-01-30
CN1219166A (zh) 1999-06-09
NZ332711A (en) 2000-06-23
JP2000511175A (ja) 2000-08-29
EA001561B1 (ru) 2001-04-23
BG63940B1 (bg) 2003-07-31
EP0901466A1 (en) 1999-03-17
AU2680397A (en) 1997-12-09
CZ366898A3 (cs) 1999-02-17
EP0901466B1 (en) 2001-10-31
DE69707865D1 (de) 2001-12-06
CN1077885C (zh) 2002-01-16
AU713286B2 (en) 1999-11-25
HK1019585A1 (en) 2000-02-18
SK157798A3 (en) 1999-04-13
EE9800397A (et) 1999-06-15
PL329929A1 (en) 1999-04-26
KR20000011095A (ko) 2000-02-25
WO1997044315A1 (en) 1997-11-27
DK0901466T3 (da) 2002-02-18
CZ294063B6 (cs) 2004-09-15
NO985326L (no) 1999-01-14
BR9710841A (pt) 1999-08-17
NO985326D0 (no) 1998-11-16
EE03965B1 (et) 2003-02-17
EA199800988A1 (ru) 1999-04-29
CA2253342A1 (en) 1997-11-27

Similar Documents

Publication Publication Date Title
IL126832A0 (en) Biphenylsulfonamide matrix metalloproteinase inhibitors
AU6894800A (en) Caspase inhibitors and uses thereof
GB9801690D0 (en) Therapeutic agents
NZ332762A (en) Isobutylgaba and its derivatives for the treatment of pain
IL128900A0 (en) Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitor
PL312196A1 (en) Heterocyclic phenyl compounds as inhibitors of cyclooxygenase-2
AU2483000A (en) Treatment of asthma with mek inhibitors
IL141410A0 (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
AU4284196A (en) Substituted biphenyl compounds for the treatment of inflammation
NZ285846A (en) Arylsulphonamido-substituted hydroxamic acids and preparation and medicaments useful for inhibiting metalloproteinases
NZ333550A (en) Matrix metalloproteinase inhibitors for inhibiting the release of TNF
AU1314300A (en) Methods and compositions for inhibiting polymerization of ethylenically unsaturated hydrocarbons
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
AU9066498A (en) Substituted 6-alkylphenanthridines
AU2001255646A1 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
DE69736945D1 (de) Biphenylverbindungen sowie ihre anwendung als östrogene mittel
CY2225B1 (en) Organic compounds
AU3729397A (en) Butyric acid matrix metalloproteinase inhibitors
BR9906803A (pt) Processo para tratamento de copd
ZA982808B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia